PDT Partners LLC Grows Stake in Vir Biotechnology, Inc. (NASDAQ:VIR)

PDT Partners LLC grew its stake in shares of Vir Biotechnology, Inc. (NASDAQ:VIR) by 34.4% in the 3rd quarter, Holdings Channel.com reports. The fund owned 220,821 shares of the company’s stock after acquiring an additional 56,494 shares during the period. PDT Partners LLC’s holdings in Vir Biotechnology were worth $1,654,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of VIR. Blue Trust Inc. increased its stake in Vir Biotechnology by 143.5% during the 3rd quarter. Blue Trust Inc. now owns 3,989 shares of the company’s stock valued at $30,000 after purchasing an additional 2,351 shares in the last quarter. Innealta Capital LLC bought a new stake in shares of Vir Biotechnology during the second quarter valued at approximately $32,000. nVerses Capital LLC purchased a new position in Vir Biotechnology in the 3rd quarter worth approximately $56,000. Magnetar Financial LLC bought a new position in Vir Biotechnology in the 2nd quarter valued at approximately $95,000. Finally, Quest Partners LLC boosted its stake in Vir Biotechnology by 142.1% during the 2nd quarter. Quest Partners LLC now owns 12,695 shares of the company’s stock valued at $113,000 after purchasing an additional 7,452 shares during the last quarter. Hedge funds and other institutional investors own 65.32% of the company’s stock.

Insider Activity

In other news, Director Janet Napolitano sold 12,190 shares of Vir Biotechnology stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $7.80, for a total transaction of $95,082.00. Following the transaction, the director now directly owns 11,616 shares of the company’s stock, valued at $90,604.80. The trade was a 51.21 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold a total of 15,940 shares of company stock valued at $127,410 in the last 90 days. Company insiders own 15.60% of the company’s stock.

Analysts Set New Price Targets

VIR has been the topic of a number of research analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $110.00 price target on shares of Vir Biotechnology in a report on Wednesday, November 20th. Needham & Company LLC restated a “buy” rating and set a $19.00 target price on shares of Vir Biotechnology in a research note on Wednesday, November 20th. Finally, Barclays reduced their price target on shares of Vir Biotechnology from $28.00 to $26.00 and set an “overweight” rating for the company in a research note on Monday, November 4th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $36.40.

Vir Biotechnology Price Performance

Shares of NASDAQ:VIR opened at $7.96 on Friday. Vir Biotechnology, Inc. has a 52-week low of $6.56 and a 52-week high of $13.09. The stock’s 50-day simple moving average is $7.90 and its two-hundred day simple moving average is $8.79.

Vir Biotechnology (NASDAQ:VIR) last posted its quarterly earnings data on Thursday, October 31st. The company reported ($1.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.05) by ($0.51). Vir Biotechnology had a negative return on equity of 36.71% and a negative net margin of 678.40%. The business had revenue of $2.38 million during the quarter, compared to analysts’ expectations of $5.54 million. During the same period in the previous year, the business posted ($1.22) EPS. The business’s quarterly revenue was down 9.8% compared to the same quarter last year. Equities analysts anticipate that Vir Biotechnology, Inc. will post -3.36 earnings per share for the current year.

About Vir Biotechnology

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).